Does Cosentyx Affect Hunger or Cravings?
Cosentyx (secukinumab), an IL-17 inhibitor for psoriasis, psoriatic arthritis, and ankylosing spondylitis, lists no direct changes to hunger or cravings in its official prescribing information or common side effects.[1] Clinical trials and post-marketing data focus on infections, diarrhea, and upper respiratory issues, without mentioning appetite alterations as frequent or notable.[2]
What Side Effects Are Most Commonly Reported?
Patients report diarrhea (up to 11%), upper respiratory infections (up to 14%), and nasopharyngitis most often. Gastrointestinal effects like nausea or abdominal pain occur in under 5%, but these rarely link to hunger shifts. No trial data flags weight gain, loss, or appetite changes as adverse events.[1][2]
Can It Indirectly Influence Appetite?
Some immunomodulators cause GI upset that might temporarily suppress eating, but Cosentyx trials show no significant weight changes or appetite-related complaints. A small subset of patients notes mild nausea early in treatment, potentially curbing meals short-term, though this resolves quickly.[3] No evidence ties it to increased cravings.
How Does Cosentyx Compare to Other Biologics on Appetite?
Unlike TNF inhibitors (e.g., Humira), which sometimes cause weight gain possibly from appetite boosts, Cosentyx shows neutral weight impact in studies.[4] IL-23 inhibitors like Tremfya also lack appetite effects. Patient forums occasionally mention unrelated diet changes due to psoriasis symptom relief, not the drug itself.
What Do Real Patients Say About Weight or Eating?
On platforms like Drugs.com and Reddit, reviews rarely mention hunger or cravings—focus is on skin clearing and injection comfort. Average rating: 7.2/10 from 200+ reviews, with <1% citing appetite issues. Weight stability is typical.[5]
When Should You Watch for Appetite Changes?
Contact a doctor if persistent nausea or GI issues emerge, as they could signal infection risk rather than direct appetite effects. Monitor during dose escalation. No black-box warnings involve eating patterns.[1]
[1]: Cosentyx Prescribing Information (Novartis)
[2]: FDA Label for Secukinumab
[3]: ClinicalTrials.gov: Secukinumab Trials (e.g., NCT01695239)
[4]: JAMA Dermatology Review on Biologics and Weight (2020)
[5]: Drugs.com Cosentyx Reviews